Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar aminvestments (52.72) Submitted: 3/18/2008 3:26:05 AM : Outperform Start Price: $8.30 CRME Score: -100.10

baby boomers ageing

Featured Broker Partners


Advertisement